Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chong, Huihui ^a   Yao, Xue ^a   Zhang, Chao ^a   Cai, Lifeng ^b   Cui, Sheng ^a   Wang, Youchun ^c   He, Yuxian ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

^b BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

^c NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUVIRTIDE; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; ENFUVIRTIDE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MALEIMIDE DERIVATIVE; PEPTIDE; PEPTIDE FRAGMENT;

ALPHA HELIX; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG CONFORMATION; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; GROWTH INHIBITION; GROWTH RATE; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; INTERMETHOD COMPARISON; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR CLONING; NONHUMAN; OUTCOME ASSESSMENT; SITE DIRECTED MUTAGENESIS; VIRUS ENTRY; VIRUS REPLICATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANTIVIRAL RESISTANCE; BIOPHYSICS; CELL LINE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; GENETICS; MOLECULAR GENETICS; MUTATION; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; BIOPHYSICAL PROCESSES; CELL LINE; DRUG DISCOVERY; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; MALEIMIDES; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN STRUCTURE, SECONDARY; VIRUS INTERNALIZATION; VIRUS REPLICATION;

EID: 84863275072     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032599     Document Type: Article

References (58)

1. Chan DC, Fass D, Berger JM, Kim PS, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
2. Tan K, Liu J, Wang J, Shen S, Lu M, (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94: 12303-12308.
3. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC, (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
4. Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, et al. (2010) Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions. PLoS Pathog 6: e1000880.
5. Berkhout B, Sanders RW, (2011) Molecular strategies to design an escape-proof antiviral therapy. Antiviral Res 92: 7-14.
6. Eggink D, Berkhout B, Sanders RW, (2010) Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des 16: 3716-3728.
7. Steffen I, Pohlmann S, (2010) Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr Pharm Des 16: 1143-1158.
8. Jiang S, Lin K, Strick N, Neurath AR, (1993) HIV-1 inhibition by a peptide. Nature 365: 113.
9. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ, (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774.
10. Chan DC, Kim PS, (1998) HIV entry and its inhibition. Cell 93: 681-684.
11. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, et al. (1998) Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302-1307.
12. Lalezari JP, Henry K, O'Hearn M, Montaner JS, Piliero PJ, et al. (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348: 2175-2185.
13. Patel IH, Zhang X, Nieforth K, Salgo M, Buss N, (2005) Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin Pharmacokinet 44: 175-186.
14. Eggink D, Baldwin CE, Deng Y, Langedijk JP, Lu M, et al. (2008) Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol 82: 6678-6688.
15. He Y, Cheng J, Lu H, Li J, Hu J, et al. (2008) Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A 105: 16332-16337.
16. He Y, Xiao Y, Song H, Liang Q, Ju D, et al. (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283: 11126-11134.
17. Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, et al. (2007) Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci U S A 104: 12772-12777.
18. Naider F, Anglister J, (2009) Peptides in the treatment of AIDS. Curr Opin Struct Biol 19: 473-482.
19. Nishikawa H, Nakamura S, Kodama E, Ito S, Kajiwara K, et al. (2009) Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol 41: 891-899.
20. Eggink D, Langedijk JP, Bonvin AM, Deng Y, Lu M, et al. (2009) Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors. J Biol Chem 284: 26941-26950.
21. Yao X, Chong H, Zhang C, Waltersperger S, Wang M, et al. (2012) Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor Sifuvirtide. J Biol Chem.
22. Wexler-Cohen Y, Shai Y, (2007) Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J 21: 3677-3684.
23. Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, et al. (2009) Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci U S A 106: 5801-5806.
24. Stoddart CA, Nault G, Galkina SA, Thibaudeau K, Bakis P, et al. (2008) Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice. J Biol Chem 283: 34045-34052.
25. Xie D, Yao C, Wang L, Min W, Xu J, et al. (2010) An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother 54: 191-196.
26. He Y, Cheng J, Li J, Qi Z, Lu H, et al. (2008) Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol 82: 6349-6358.
27. McCutchan FE, (2000) Understanding the genetic diversity of HIV-1. Aids 14 (Suppl 3): S31-44.
28. Taylor BS, Hammer SM, (2008) The challenge of HIV-1 subtype diversity. N Engl J Med 359: 1965-1966.
29. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53 (Suppl 1): S10-14.
30. Lu L, Jia M, Ma Y, Yang L, Chen Z, et al. (2008) The changing face of HIV in China. Nature 455: 609-611.
31. Eckert DM, Kim PS, (2001) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70: 777-810.
32. He Y, Liu S, Li J, Lu H, Qi Z, et al. (2008) Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J Virol 82: 11129-11139.
33. Naito T, Izumi K, Kodama E, Sakagami Y, Kajiwara K, et al. (2009) SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother 53: 1013-1018.
34. Palmer S, Alaeus A, Albert J, Cox S, (1998) Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates. AIDS Res Hum Retroviruses 14: 157-162.
35. Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, et al. (2002) Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother 46: 2087-2094.
36. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, et al. (2003) A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. Aids 17: F1-5.
37. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, et al. (2004) Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. Aids 18: 909-915.
38. Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, et al. (2005) Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 146: 3052-3058.
39. Hartung G, Stehle G, Sinn H, Wunder A, Schrenk HH, et al. (1999) Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Clin Cancer Res 5: 753-759.
40. Cruz LJ, Iglesias E, Aguilar JC, Quintana D, Garay HE, et al. (2001) Study of different coupling agents in the conjugation of a V3-based synthetic MAP to carrier proteins. J Pept Sci 7: 511-518.
41. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, et al. (2006) A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy. Antivir Ther 11: 35-45.
42. Abu Ajaj K, Graeser R, Fichtner I, Kratz F, (2009) In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B. Cancer Chemother Pharmacol 64: 413-418.
43. Esmaeili F, Dinarvand R, Ghahremani MH, Amini M, Rouhani H, et al. (2009) Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies. J Pharm Sci 98: 2718-2730.
44. Hamburger AE, Kim S, Welch BD, Kay MS, (2005) Steric accessibility of the HIV-1 gp41 N-trimer region. J Biol Chem 280: 12567-12572.
45. Sabin C, Corti D, Buzon V, Seaman MS, Lutje Hulsik D, et al. (2010) Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog 6: e1001195.
46. Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, et al. (2005) A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope. Proc Natl Acad Sci U S A 102: 14759-14764.
47. Takami M, Sone T, Mizumoto K, Kino K, Tsunoo H, (1992) Maleylated human serum albumin inhibits HIV-1 infection in vitro. Biochim Biophys Acta 1180: 180-186.
48. Jansen RW, Schols D, Pauwels R, De Clercq E, Meijer DK, (1993) Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol Pharmacol 44: 1003-1007.
49. Swart PJ, Beljaars E, Smit C, Pasma A, Schuitemaker H, et al. (1996) Comparative pharmacokinetic, immunologic and hematologic studies on the anti-HIV-1/2 compounds aconitylated and succinylated HSA. J Drug Target 4: 109-116.
50. Groenink M, Swart PJ, Broersen S, Kuipers M, Meijer DK, et al. (1997) Potent inhibition of replication of primary HIV type 1 isolates in peripheral blood lymphocytes by negatively charged human serum albumins. AIDS Res Hum Retroviruses 13: 179-185.
51. Jacobs A, Quraishi O, Huang X, Bousquet-Gagnon N, Nault G, et al. (2007) A covalent inhibitor targeting an intermediate conformation of the fusogenic subunit of the HIV-1 envelope complex. J Biol Chem 282: 32406-32413.
52. Derdeyn CA, Decker JM, Sfakianos JN, Wu X, O'Brien WA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358-8367.
53. Chen YH, Yang JT, Chau KH, (1974) Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry 13: 3350-3359.
54. Shu W, Liu J, Ji H, Radigen L, Jiang S, et al. (2000) Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry 39: 1634-1642.
55. He Y, Liu S, Jing W, Lu H, Cai D, et al. (2007) Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem 282: 25631-25639.
56. Chong H, Xu S, Zhang C, Nie J, Wang Y, (2009) Mutation L33M in the HR1 region of HIV-1 gp41 may play a role in T20 resistance. J Clin Virol 45: 255-258.
57. Chinnadurai R, Munch J, Kirchhoff F, (2005) Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors. Aids 19: 1401-1405.
58. Chinnadurai R, Rajan D, Munch J, Kirchhoff F, (2007) Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol 81: 6563-6572.